A Phase II Study of PTK787/ZK222584 (NSC 719335) in Patients With Unresectable Malignant Mesothelioma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Vatalanib (Primary)
- Indications Malignant-mesothelioma
- Focus Biomarker; Therapeutic Use
- 17 Mar 2011 Actual end date changed from 1 Mar 2006 to 1 Jun 2006 as reported by ClinicalTrials.gov.
- 20 May 2009 Planned number of patients changed from 40 to 47, additional investigators (Kratzke RA, Dudek A) added as reported by ClinicalTrials.gov.
- 02 Aug 2006 Status change